Skip to main content
Clinical Trials/NCT05517993
NCT05517993
Not yet recruiting
Phase 2

Effect of Gui-Lu-Er-Xian-Jiao-Wan on Intradialytic Hypotension: a Randomized Crossover Pilot Trial

Chang Gung Memorial Hospital1 site in 1 country50 target enrollmentSeptember 1, 2022

Overview

Phase
Phase 2
Intervention
Gui-Lu-Er-Xian-Jiao-Wan
Conditions
Intradialytic Hypotension
Sponsor
Chang Gung Memorial Hospital
Enrollment
50
Locations
1
Primary Endpoint
Intradialytic hypotension episode
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

Intradialytic hypotension (IDH), a common complication during hemodialysis (HD) could increase patients' morbidity and mortality. Previous studies considered that some Chinese herbal medicine (CHM) plays a complementary role in reducing the frequency of IDH. This trial is aimed to investigate the effect of Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) in patients with intradialytic hypotension.

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
December 31, 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Chang Gung Memorial Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • End stage renal disease treated with hemodialysis for ≥3 months
  • Receive a standard thrice-weekly hemodialysis schedule
  • More than 25% of hemodialysis sessions complicated by intradialytic hypotension

Exclusion Criteria

  • Active malignancy
  • Life-threatening conditions
  • Pregnancy
  • Recent participation in another clinical trial for intradialytic hypotension
  • History of hypersensitivity or contraindication to herbal medicine

Arms & Interventions

Group A

Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) 3g orally twice daily for 12 weeks.

Intervention: Gui-Lu-Er-Xian-Jiao-Wan

Outcomes

Primary Outcomes

Intradialytic hypotension episode

Time Frame: Each time of dialysis during 12-weeks study period.

Hypotension episode during hemodialysis

Secondary Outcomes

  • Early termination of hemodialysis(Each time of dialysis during 12-weeks study period.)
  • SF-36(Baseline, 12 weeks, 28 weeks)

Study Sites (1)

Loading locations...

Similar Trials